iTRAQ‑based proteomics analysis of the therapeutic effects of combined anticancer bioactive peptides and oxaliplatin on gastric cancer cells

Xu,Yanan; Li,Xian; Su,Xiulan

doi:10.3892/or.2019.7406

iTRAQ‑based proteomics analysis of the therapeutic effects of combined anticancer bioactive peptides and oxaliplatin on gastric cancer cells

Authors:
- Yanan Xu
- Xian Li
- Xiulan Su
View Affiliations

Affiliations: Department of Cell Biology, College of Basic Medicine, Capital Medical University, Beijing 100069, P.R. China, Clinical Medical Research Center, The Affiliated Hospital of Inner Mongolia Medical University, Inner Mongolia Autonomous Region 010050, P.R. China
Published online on: November 11, 2019 https://doi.org/10.3892/or.2019.7406
Pages: 201-217
Copyright: © Xu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The combination of chemotherapeutic modalities may be more effective in treating gastric cancer compared with any modality alone. Previous studies have demonstrated that the combination of anticancer bioactive peptides (ACBP) and oxaliplatin (OXA) significantly inhibited the growth of the gastric cancer cell line MKN‑45, promoted the apoptosis of MKN‑45 cells, and caused an irreversible arrest of the MKN‑45 cell cycle in the G2/M phase. In the present study, an isobaric tag for relative and absolute quantitation (iTRAQ)‑based quantitative proteomics technique was used to determine the effect of ACBP‑OXA treatment on the proteomics profile of MKN‑45 cells. Notably, a total of 6,210 proteins were detected. Proteins with a >1.2‑fold change in expression (either up‑ or downregulation) and P<0.05 were considered to be differentially expressed. A total of 256 differentially expressed proteins were identified through alignments with different groups. Compared with the control group, MKN‑45 cells treated with ACBP, OXA and ACBP‑OXA exhibited 17 (10 up‑ and 7 downregulated), 111 (27 up‑ and 84 downregulated) and 128 (53 up‑ and 75 downregulated) differentially expressed proteins, respectively. Of the 256 differentially expressed proteins, 6 (TPX2, NUSAP1, TOP2A, YAP, MKi‑67 and GPC4) were verified by the parallel reaction monitoring method, which revealed that TPX2, NUSAP1, TOP2A, YAP, MKi‑67 and GPC4 expression decreased with ACBP‑OXA treatment. The cellular localization, functional annotation and biological pathways of differentially expressed proteins were examined by Gene Ontology and Kyoto Encyclopedia of Genes and Genomes analysis. The results indicated that ACBP‑OXA may act through the ribosome or the AMP‑activated protein kinase (AMPK) signaling pathway, and the AMPK signaling pathway may be an important mediator of the inhibitory effects of ACBP‑OXA on MKN‑45 gastric cancer cells. In summary, iTRAQ‑based proteomics analysis of the effect of ACBP‑OXA on MKN‑45 cells may guide future therapeutic strategies for gastric cancer. In addition, the present study may help provide new insights into the therapeutic role of combined ACBP and OXA in gastric cancer.

View Figures

View References

1	Ferro A, Peleteiro B, Malvezzi M, Bosetti C, Bertuccio P, Levi F, Negri E, La Vecchia C and Lunet N: Worldwide trends in gastric cancer mortality (1980–2011), with predictions to 2015, and incidence by subtype. Eur J Cancer. 50:1330–1344. 2014. View Article : Google Scholar : PubMed/NCBI
2	Karimi P, Islami F, Anandasabapathy S, Freedman ND and Kamangar F: Gastric cancer: Descriptive epidemiology, risk factors, screening, and prevention. Cancer Epidemiol Biomarkers Prev. 23:700–713. 2014. View Article : Google Scholar : PubMed/NCBI
3	Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015. View Article : Google Scholar : PubMed/NCBI
4	Suzuki S, Gotoda T, Hatta W, Oyama T, Kawata N, Takahashi A, Yoshifuku Y, Hoteya S, Nakagawa M, Hirano M, et al: Survival benefit of additional surgery after non-curative endoscopic submucosal dissection for early gastric cancer: A propensity score matching analysis. Ann Surg Oncol. 24:3353–3360. 2017. View Article : Google Scholar : PubMed/NCBI
5	Ohnita K, Isomoto H, Shikuwa S, Yajima H, Minami H, Matsushima K, Akazawa Y, Yamaguchi N, Fukuda E, Nishiyama H, et al: Early and long-term outcomes of endoscopic submucosal dissection for early gastric cancer in a large patient series. Exp Ther Med. 7:594–598. 2014. View Article : Google Scholar : PubMed/NCBI
6	Di Caro S, Tao H, Grillo A, Franceschi F, Elia C, Zocco MA, Gasbarrini G, Sepulveda AR and Gasbarrini A: Bacillus clausii effect on gene expression pattern in small bowel mucosa using DNA microarray analysis. Eur J Gastroenterol Hepatol. 17:951–960. 2005. View Article : Google Scholar : PubMed/NCBI
7	Ray B, Gupta B and Mehrotra R: Binding of platinum derivative, oxaliplatin to deoxyribonucleic acid: Structural insight into antitumor action. J Biomol Struct Dyn. 37:3838–3847. 2019. View Article : Google Scholar : PubMed/NCBI
8	Drott J, Starkhammar H, Kjellgren K and Berterö C: Neurotoxic side effects early in the oxaliplatin treatment period in patients with colorectal cancer. Oncol Nurs Forum. 45:690–697. 2018.PubMed/NCBI
9	Su LY, Xin HY, Liu YL, Zhang JL, Xin HW and Su XL: Anticancer bioactive peptide (ACBP) inhibits gastric cancer cells by upregulating growth arrest and DNA damage-inducible gene 45A (GADD45A). Tumour Biol. 35:10051–10056. 2014. View Article : Google Scholar : PubMed/NCBI
10	Zhao YY, Peng SD and Su XL: Effects of anti-cancer bioactive peptide on cell cycle in human nasopharyngeal carcinoma strain CNE. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 41:607–611. 2006.(In Chinese). PubMed/NCBI
11	Xing Z, Yu L, Li X and Su X: Anticancer bioactive peptide-3 inhibits human gastric cancer growth by targeting miR-338-5p. Cell Biosci. 6:532016. View Article : Google Scholar : PubMed/NCBI
12	Su X, Dong C, Zhang J, Su L, Wang X, Cui H and Chen Z: Combination therapy of anti-cancer bioactive peptide with Cisplatin decreases chemotherapy dosing and toxicity to improve the quality of life in xenograft nude mice bearing human gastric cancer. Cell Biosci. 4:72014. View Article : Google Scholar : PubMed/NCBI
13	Li X, Wu H, Ouyang X, Zhang B and Su X: New bioactive peptide reduces the toxicity of chemotherapy drugs and increases drug sensitivity. Oncol Rep. 38:129–140. 2017. View Article : Google Scholar : PubMed/NCBI
14	Su L, Xu G, Shen J, Tuo Y, Zhang X, Jia S, Chen Z and Su X: Anticancer bioactive peptide suppresses human gastric cancer growth through modulation of apoptosis and the cell cycle. Oncol Rep. 23:3–9. 2010.PubMed/NCBI
15	Moulder R, Bhosale SD, Goodlett DR and Lahesmaa R: Analysis of the plasma proteome using iTRAQ and TMT-based Isobaric labeling. Mass Spectrom Rev. 37:583–606. 2018. View Article : Google Scholar : PubMed/NCBI
16	Zhang P, Dai Y, Xiong J, Zhu S, Zhao M, Ding S and Li J: iTRAQ-based differential proteomics analysis of the brains in a rat model of delayedcarbon monoxide encephalopathy. Brain Res Bull. 137:329–337. 2018. View Article : Google Scholar : PubMed/NCBI
17	Li Y, Wang Z, Zhao Z and Cui Y: iTRAQ-based proteome profiling of hyposaline responses in zygotes of the Pacific oyster Crassostrea gigas. Comp Biochem Physiol Part D Genomics Proteomics. 30:14–24. 2019. View Article : Google Scholar : PubMed/NCBI
18	Takaishi S, Okumura T, Tu S, Wang SS, Shibata W, Vigneshwaran R, Gordon SA, Shimada Y and Wang TC: Identification of gastric cancer stem cells using the cell surface marker CD44. Stem Cells. 27:1006–1020. 2009. View Article : Google Scholar : PubMed/NCBI
19	Zhang P, Zhu S, Zhao M, Zhao P, Zhao H, Deng J and Li J: Identification of plasma biomarkers for diffuse axonal injury in rats by iTRAQ-coupled LC-MS/MS and bioinformatics analysis. Brain Res Bull. 142:224–232. 2018. View Article : Google Scholar : PubMed/NCBI
20	Han W, Xiao R, Zhang C, Suyila Q, Li X and Su X: Selecting lncRNAs in gastric cancer cells for directed therapy with bioactive peptides and chemotherapy drugs. Oncotarget. 8:86082–86097. 2017. View Article : Google Scholar : PubMed/NCBI
21	Bhusal P, Rahiri JL, Sua B, McDonald JE, Bansal M, Hanning S, Sharma M, Chandramouli K, Harrison J, Procter G, et al: Comparing human peritoneal fluid and phosphate-buffered saline for drug delivery: Do we need bio-relevant media? Drug Deliv Transl Res. 8:708–718. 2018. View Article : Google Scholar : PubMed/NCBI
22	Thorat AA and Suryanarayanan R: Characterization of phosphate buffered saline (PBS) in frozen State and after Freeze-drying. Pharm Res. 36:982019. View Article : Google Scholar : PubMed/NCBI
23	Yu L, Yang L, An W and Su X: Anticancer bioactive peptide-3 inhibits human gastric cancer growth by suppressing gastric cancer stem cells. J Cell Biochem. 115:697–711. 2014. View Article : Google Scholar : PubMed/NCBI
24	Wisniewski JR, Zougman A, Nagaraj N and Mann M: Universal sample preparation method for proteome analysis. Nat Methods. 6:359–362. 2009. View Article : Google Scholar : PubMed/NCBI
25	Götz S, García-Gómez JM, Terol J, Williams TD, Nagaraj SH, Nueda MJ, Robles M, Talón M, Dopazo J and Conesa A: High-throughput functional annotation and data mining with the Blast2GO suite. Nucleic Acids Res. 36:3420–3435. 2008. View Article : Google Scholar : PubMed/NCBI
26	Peterson AC, Russell JD, Bailey DJ, Westphall MS and Coon JJ: Parallel reaction monitoring for high resolution and high mass accuracy quantitative, targeted proteomics. Mol Cell Proteomics. 11:1475–1488. 2012. View Article : Google Scholar : PubMed/NCBI
27	MacLean B, Tomazela DM, Shulman N, Chambers M, Finney GL, Frewen B, Kern R, Tabb DL, Liebler DC and MacCoss MJ: Skyline: An open source document editor for creating and analyzing targeted proteomics experiments. Bioinformatics. 26:966–968. 2010. View Article : Google Scholar : PubMed/NCBI
28	Ito Y, Yoshikawa T, Fujiwara M, Kojima H, Matsui T, Mochizuki Y, Cho H, Aoyama T, Ito S, Misawa K, et al: Quality of life and nutritional consequences after aboral pouch reconstruction following total gastrectomy for gastric cancer: Randomized controlled trial CCG1101. Gastric Cancer. 19:977–985. 2016. View Article : Google Scholar : PubMed/NCBI
29	Kalfusova A, Hilska I, Krskova L, Kalinova M, Linke Z and Kodet R: Gastrointestinal stromal tumors-quantitative detection of the Ki-67, TPX2, TOP2A, and hTERT telomerase subunit mRNA levels to determine proliferation activity and a potential for aggressive biological behavior. Neoplasma. 63:484–492. 2016. View Article : Google Scholar : PubMed/NCBI
30	Villanueva MT: Combination therapy: Update on gastric cancer in East Asia. Nat Rev Clin Oncol. 8:6902011. View Article : Google Scholar : PubMed/NCBI
31	Berretta M, Taibi R, Bearz A, La Mura N, Berretta S, Tirelli U and Frustaci S: Dysphonia as an unusual toxic event of oxaliplatin-based chemotherapy. J Chemother. 16:595–598. 2004. View Article : Google Scholar : PubMed/NCBI
32	Wadsworth P: Tpx2. Curr Biol. 25:R1156–R1158. 2015. View Article : Google Scholar : PubMed/NCBI
33	Neumayer G, Belzil C, Gruss OJ and Nguyen MD: TPX2: Of spindle assembly, DNA damage response, and cancer. Cell Mol Life Sci. 71:3027–3047. 2014. View Article : Google Scholar : PubMed/NCBI
34	Alfaro-Aco R and Petry S: How TPX2 helps microtubules branch out. Cell Cycle. 16:1560–1561. 2017. View Article : Google Scholar : PubMed/NCBI
35	Lee SY, Kim EY, Kim KH and Lee KA: Bcl2l10, a new Tpx2 binding partner, is a master regulator of Aurora kinase A in mouse oocytes. Cell Cycle. 15:3296–3305. 2016. View Article : Google Scholar : PubMed/NCBI
36	Garrido G and Vernos I: Non-centrosomal TPX2-dependent regulation of the Aurora A Kinase: Functional implications for healthy and pathological cell division. Front Oncol. 6:882016. View Article : Google Scholar : PubMed/NCBI
37	Grover A, Singh R, Shandilya A, Priyandoko D, Agrawal V, Bisaria VS, Wadhwa R, Kaul SC and Sundar D: Ashwagandha derived withanone targets TPX2-Aurora A complex: Computational and experimental evidence to its anticancer activity. PLoS One. 7:e308902012. View Article : Google Scholar : PubMed/NCBI
38	Pascreau G, Eckerdt F, Lewellyn AL, Prigent C and Maller JL: Phosphorylation of p53 is regulated by TPX2-Aurora A in xenopus oocytes. J Biol Chem. 284:5497–5505. 2009. View Article : Google Scholar : PubMed/NCBI
39	Liu Z, Guan C, Lu C, Liu Y, Ni R, Xiao M and Bian Z: High NUSAP1 expression predicts poor prognosis in colon cancer. Pathol Res Pract. 214:968–973. 2018. View Article : Google Scholar : PubMed/NCBI
40	Gordon CA, Gong X, Ganesh D and Brooks JD: NUSAP1 promotes invasion and metastasis of prostate cancer. Oncotarget. 8:29935–29950. 2017. View Article : Google Scholar : PubMed/NCBI
41	Han G, Wei Z, Cui H, Zhang W, Wei X, Lu Z and Bai X: NUSAP1 gene silencing inhibits cell proliferation, migration and invasion through inhibiting DNMT1 gene expression in human colorectal cancer. Exp Cell Res. 367:216–221. 2018. View Article : Google Scholar : PubMed/NCBI
42	Ye M, He Z, Dai W, Li Z, Chen X and Liu J: A TOP2A-derived cancer panel drives cancer progression in papillary renal cell carcinoma. Oncol Lett. 16:4169–4178. 2018.PubMed/NCBI
43	Engstrom MJ, Ytterhus B, Vatten LJ, Opdahl S and Bofin AM: TOP2A gene copy number change in breast cancer. J Clin Pathol. 67:420–425. 2014. View Article : Google Scholar : PubMed/NCBI
44	de Resende MF, Vieira S, Chinen LT, Chiappelli F, da Fonseca FP, Guimarães GC, Soares FA, Neves I, Pagotty S, Pellionisz PA, et al: Prognostication of prostate cancer based on TOP2A protein and gene assessment: TOP2A in prostate cancer. J Transl Med. 11:362013. View Article : Google Scholar : PubMed/NCBI
45	Zhang J, Yang YC, Zhu JS, Zhou Z and Chen WX: Clinicopathologic characteristics of YES-associated protein 1 overexpression and its relationship to tumor biomarkers in gastric cancer. Int J Immunopathol Pharmacol. 25:977–987. 2012. View Article : Google Scholar : PubMed/NCBI
46	Chang HL, Chen HA, Bamodu OA, Lee KF, Tzeng YM, Lee WH and Tsai JT: Ovatodiolide suppresses yes-associated protein 1-modulated cancer stem cell phenotypes in highly malignant hepatocellular carcinoma and sensitizes cancer cells to chemotherapy in vitro. Toxicol In Vitro. 51:74–82. 2018. View Article : Google Scholar : PubMed/NCBI
47	Kang W, Tong JH, Chan AW, Lee TL, Lung RW, Leung PP, So KK, Wu K, Fan D, Yu J, et al: Yes-associated protein 1 exhibits oncogenic property in gastric cancer and its nuclear accumulation associates with poor prognosis. Clin Cancer Res. 17:2130–2139. 2011. View Article : Google Scholar : PubMed/NCBI
48	Lee SE, Lee JU, Lee MH, Ryu MJ, Kim SJ, Kim YK, Choi MJ, Kim KS, Kim JM, Kim JW, et al: RAF kinase inhibitor-independent constitutive activation of Yes-associated protein 1 promotes tumor progression in thyroid cancer. Oncogenesis. 2:e552013. View Article : Google Scholar : PubMed/NCBI
49	Li HH, Qi LN, Ma L, Chen ZS, Xiang BD and Li LQ: Effect of KI-67 positive cellular index on prognosis after hepatectomy in Barcelona Clinic Liver Cancer stage A and B hepatocellular carcinoma with microvascular invasion. Onco Targets Ther. 11:4747–4754. 2018. View Article : Google Scholar : PubMed/NCBI
50	Yoshikawa K, Shimada M, Higashijima J, Nakao T, Nishi M, Takasu C, Kashihara H, Eto S and Bando Y: Ki-67 and survivin as predictive factors for rectal cancer treated with preoperative chemoradiotherapy. Anticancer Res. 38:1735–1739. 2018.PubMed/NCBI
51	Warli SM, Kadar DD and Siregar GP: Ki-67 expression as a predictive factor of muscle invasion in bladder cancer. Open Access Maced J Med Sci. 6:260–262. 2018. View Article : Google Scholar : PubMed/NCBI
52	Belinsky I, Murchison AP, Evans JJ, Andrews DW, Farrell CJ, Casey JP, Curtis MT, Nowak Choi KA, Werner-Wasik M and Bilyk JR: Spheno-orbital meningiomas: An analysis based on World health organization classification and Ki-67 proliferative index. Ophthalmic Plast Reconstr Surg. 34:143–150. 2018. View Article : Google Scholar : PubMed/NCBI
53	Ishibashi N, Nishimaki H, Maebayashi T, Hata M, Adachi K, Sakurai K, Masuda S and Okada M: Changes in the Ki-67 labeling index between primary breast cancer and metachronous metastatic axillary lymph node: A retrospective observational study. Thorac Cancer. 10:96–102. 2019. View Article : Google Scholar : PubMed/NCBI
54	Dono R: Glypican 4 down-regulation in pluripotent stem cells as a potential strategy to improve differentiation and to impair tumorigenicity of cell transplants. Neural Regen Res. 10:1576–1577. 2015. View Article : Google Scholar : PubMed/NCBI
55	Zhao D, Liu S, Sun L, Zhao Z, Liu S, Kuang X, Shu J and Luo B: Glypican-4 gene polymorphism (rs1048369) and susceptibility to Epstein-Barr virus-associated and -negative gastric carcinoma. Virus Res. 220:52–56. 2016. View Article : Google Scholar : PubMed/NCBI